Claros gains $7.8M in first round of venture finance

Claros Diagnostics has garnered $7.8 million in its first round of financing, with much of the money earmarked for the development of its handheld diagnostic testing system. The round was led by Oxford Bioscience Partners with additional investments coming from Bioventures Investors, Accelerated Technologies Partners, and Commons Capital. Claros says its diagnostic device will enable a physician to analyze a blood sample within the time it takes for a regular office visit.

- here's the release for more information

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.